Cardiovascular disease is the major cause of morbidity and mortality in breast cancer survivors. Chemotherapy contributes to this risk. We aimed to define the mechanisms of long-term vascular dysfunction caused by neoadjuvant chemotherapy (NACT) and identify novel therapeutic targets. We studied arteries from postmenopausal women who had undergone breast cancer treatment using docetaxel, doxorubicin, and cyclophosphamide (NACT) and from women with no history of such treatment matched for key clinical parameters. We explored mechanisms in WT and Nox4–/– mice and in human microvascular endothelial cells. Endothelium-dependent, NO-mediated vasodilatation was severely impaired in patients after NACT, while endothelium-independent responses remained normal. This was mimicked by a 24-hour exposure of arteries to NACT agents ex vivo. When applied individually, only docetaxel impaired endothelial function in human vessels. Mechanistic studies showed that NACT increased inhibitory eNOS phosphorylation of threonine 495 in a Rho-associated protein kinase–dependent (ROCK-dependent) manner and augmented vascular superoxide and hydrogen peroxide production and NADPH oxidase activity. Docetaxel increased expression of the NADPH oxidase NOX4 in endothelial and smooth muscle cells and NOX2 in the endothelium. A NOX4 increase in human arteries may be mediated epigenetically by diminished DNA methylation of the NOX4 promoter. Docetaxel induced endothelial dysfunction and hypertension in mice, and these were prevented in Nox4–/– mice and by pharmacological inhibition of Nox4 or Rock. Commonly used chemotherapeutic agents and, in particular, docetaxel alter vascular function by promoting the inhibitory phosphorylation of eNOS and enhancing ROS production by NADPH oxidases.
Piotr Szczepaniak, Mateusz Siedlinski, Diana Hodorowicz-Zaniewska, Ryszard Nosalski, Tomasz P. Mikolajczyk, Aneta M. Dobosz, Anna Dikalova, Sergey Dikalov, Joanna Streb, Katarzyna Gara, Pawel Basta, Jaroslaw Krolczyk, Joanna Sulicka-Grodzicka, Ewelina Jozefczuk, Anna Dziewulska, Blessy Saju, Iwona Laksa, Wei Chen, John Dormer, Maciej Tomaszewski, Pasquale Maffia, Marta Czesnikiewicz-Guzik, Filippo Crea, Agnieszka Dobrzyn, Javid Moslehi, Tomasz Grodzicki, David G. Harrison, Tomasz J. Guzik
Title and authors | Publication | Year |
---|---|---|
Genetic imputation of kidney transcriptome, proteome and multi-omics illuminates new blood pressure and hypertension targets
Xu X, Khunsriraksakul C, Eales JM, Rubin S, Scannali D, Saluja S, Talavera D, Markus H, Wang L, Drzal M, Maan A, Lay AC, Prestes PR, Regan J, Diwadkar AR, Denniff M, Rempega G, Ryszawy J, Król R, Dormer JP, Szulinska M, Walczak M, Antczak A, Matías-García PR, Waldenberger M, Woolf AS, Keavney B, Zukowska-Szczechowska E, Wystrychowski W, Zywiec J, Bogdanski P, Danser AH, Samani NJ, Guzik TJ, Morris AP, Liu DJ, Charchar FJ, Tomaszewski M |
Nature Communications | 2024 |
Reactive oxygen species in hypertension.
Camargo LL, Rios FJ, Montezano AC, Touyz RM |
Nature reviews. Cardiology | 2024 |
Impact of Radiation Therapy on Serum Humanin and MOTS-c Levels in Patients with Lung or Breast Cancer.
Kavak AG, Karslioglu I, Saracaloglu A, Demiryürek S, Demiryürek AT |
Current radiopharmaceuticals | 2024 |
Maternal high glucose and fat diet exposure impaired vascular constriction via miR-325-3P/SHIP2/NOX2 pathway axis in offspring vessels
Ji B, Deng F, Zhou B, Zhao C, Lei J, Xu T, Qiu J, Zhang M, Zhang Y, Wei M, Gao Q |
Cellular and Molecular Life Sciences: CMLS | 2024 |
Epigenetic Signatures in Arterial Hypertension: Focus on the Microvasculature
Mengozzi A, Costantino S, Mongelli A, Mohammed SA, Gorica E, Delfine V, Masi S, Virdis A, Ruschitzka F, Paneni F |
International journal of molecular sciences | 2023 |
Targeting cytokine-like protein FAM3D lowers blood pressure in hypertension.
Shen Y, Dong Z, Fan F, Li K, Zhu S, Dai R, Huang J, Xie N, He L, Gong Z, Yang X, Tan J, Liu L, Yu F, Tang Y, You Z, Xi J, Wang Y, Kong W, Zhang Y, Fu Y |
Cell reports. Medicine | 2023 |
Maternal exercise represses Nox4 via SIRT1 to prevent vascular oxidative stress and endothelial dysfunction in SHR offspring
Zhang Y, Shan M, Ding X, Sun H, Qiu F, Shi L |
Frontiers in Endocrinology | 2023 |
Identification of NOX4 as a New Biomarker in Hepatocellular Carcinoma and Its Effect on Sorafenib Therapy.
Li HZ, Liu QQ, Chang DH, Li SX, Yang LT, Zhou P, Deng JB, Huang CH, Xiao YD |
Biomedicines | 2023 |
Systemic and local vascular inflammation and arterial reactive oxygen species generation in patients with advanced cardiovascular diseases
Sulicka-Grodzicka J, Szczepaniak P, Jozefczuk E, Urbanski K, Siedlinski M, Niewiara Ł, Guzik B, Filip G, Kapelak B, Wierzbicki K, Korkosz M, Guzik TJ, Mikolajczyk TP |
Frontiers in Cardiovascular Medicine | 2023 |
Clinical Pathway for Coronary Atherosclerosis in Patients Without Conventional Modifiable Risk Factors: JACC State-of-the-Art Review
Figtree GA, Vernon ST, Harmer JA, Gray MP, Arnott C, Bachour E, Barsha G, Brieger D, Brown A, Celermajer DS, Channon KM, Chew NW, Chong JJ, Chow CK, Cistulli PA, Ellinor PT, Grieve SM, Guzik TJ, Hagström E, Jenkins A, Jennings G, Keech AC, Kott KA, Kritharides L, Mamas MA, Mehran R, Meikle PJ, Natarajan P, Negishi K, O\u2019Sullivan J, Patel S, Psaltis PJ, Redfern J, Steg PG, Sullivan DR, Sundström J, Vogel B, Wilson A, Wong D, Bhatt DL, Kovacic JC, Nicholls SJ |
Journal of the American College of Cardiology | 2023 |
Endothelin-based markers for endothelial dysfunction in chemotherapy-induced cardiotoxicity
Boutin G, Yuzugulen J, Pranjol MZ |
Journal of Molecular and Cellular Cardiology Plus | 2023 |
Treatment-related acute toxicity with adjuvant systemic treatment among patients with HER2-positive early invasive breast cancer: a national population-based cohort study
Gannon MR, Dodwell D, Miller K, Medina J, Clements K, Horgan K, Park MH, Cromwell DA |
BMJ Oncology | 2023 |
Emerging mitochondrial signaling mechanisms in cardio-oncology: beyond oxidative stress
Bikomeye JC, Terwoord JD, Santos JH, Beyer AM |
American journal of physiology. Heart and circulatory physiology | 2022 |